My Medication Side Effects Are Too Popular

"Dear Directors, we can attack Shinming Pharma in many ways.

Williams thought about it:

"For example, slowing down their clinical steps, after all, many countries have different clinical regulations,

: Maybe their medicines can be quickly finished in the East

Is it not excessive for some drugs to require an observation period of more than one year?

clinical, but not necessarily in other countries

"Also, some side effects can be artificially created to reduce people's expectations for this drug. No matter how good a new drug is, but

If it's not safe enough, how can you compete with us?

"We can also think of some solutions from the political axe in the east, such as promising to reduce the price of some of our medicines in the east, in exchange for their

Suppression of Xinming Pharmaceutical

"We can even talk to other pharmaceutical companies for deeper cooperation and let them join us in suppressing Xinming Pharmaceutical.

"Xinming Pharma has started clinical trials around the world, coupled with updating production lines, acquiring other pharmaceutical companies, and promoting it around the world, capital is quickly consumed.

"We can pull Xinming Pharmaceuticals into a war of attrition for propaganda, can Xinming Pharmaceuticals afford it?

The same method, different companies display, the effect will be completely different.

Rui's directors all nodded and approved this method, and this method can restrict all new drugs of Xinming Pharmaceutical.

Mr. Fu, Pfizer began to popularize the concept of drug safety in the media.Claims that the drug has only been tested for a few years, or even more than ten years

Check to see if it is safe.

"Otherwise it will be with Johnson & Johnson

In the end, it endangers the health of others, and even makes people pay for their lives.

"After Pfizer's report was published, many pharmaceutical companies followed it, including some political axe organizations.

Fu Gao listened to the assistant's report and put down a document from Qianzhong

"Pfizer has taken another shot? This time, it is attacking our new drug that has not yet been launched from the perspective of safety?

This method is not very clever, but because it is Pfizer and other top pharmaceutical companies, it will have a greater impact on Xinming Pharmaceutical.

And this can be regarded as a way to injure one thousand and one hundred and eight hundred. After all, other pharmaceutical companies also have to launch new drugs.

No top pharmaceutical company has been making money by selling several drugs. If these drugs are very profitable, other pharmaceutical companies will soon join in.

If you don't make money, you won't be able to keep your status as a top pharmaceutical company.

"More than that, there were also some problems with our channels for purchasing raw materials before. Some companies directly cut off their cooperation with us, and their old

The boards have also been replaced.

The assistant's words made Fu Liang frown: "Have you been compensated for the liquidated damages?"

"It was paid to us. But we needed materials, and soon the production approval for the hair growth medicine came down. At that time, we didn't have the materials, so how could we produce new medicines?

Fu Liang narrowed his eyes: "Playing with me to draw wages from the bottom of the pot? Do you think this will stop us?

"Okay, I originally planned to have a good time with them, but now that I know what he did with the 3.2s, I can solve it better.

"Cutting off raw materials, suppressing fishing boats, and increasing capital investment in the eastern market, they have no intentions. This shows that they regard our Xinming Pharmaceutical as a competitor.

rival.

Once upon a time, would the world's No. [-] pharmaceutical company like Pfizer put Xinming Pharmaceutical in the eyes?

It took only a few months for Xinming Pharmaceutical to be regarded as a competitor by the world's top pharmaceutical companies.

But what Fu Liang wants is not to compete with top pharmaceutical companies such as Pfizer, but to overpower them!

To become the world's first pharmaceutical company!

"Investigate, Pfizer's current best-selling drug types on the market are treatments, I want to let their drug sales business be fully down.

Fu Liang's face was cold, he would develop whatever Pfizer developed, so that Pfizer's drugs would be eliminated!

PS: Ask for flowers, ask for evaluation, ask for automatic subscription!!!

Chapter [-]: Pfizer's Most Profitable Drug!System Upgrade

The next day, there was a Pfizer sales statistics table on Fu Liang's desk.

Fu Liang had told the assistant before that the assistant was already prepared.

The statistical table not only distinguishes chemical pharmaceuticals and biopharmaceuticals, but also details the role of drugs, the time of listing, and the sales situation in recent years.

Not only Pfizer's, but also some best-selling drugs of other pharmaceutical companies are counted.

Topping the list is AbbVie's Humira, a drug for arthritis, rheumatism, ankylosing spondylitis, and more, with sales of two last year.

billions of dollars.

But this drug cannot break the record Pfizer once set with Viagra, because the sales of this drug have reached their peak and are currently showing a decline.

trend.

However, this drug has been selling well for seven years, and the sales in each of these seven years have not been less than [-] billion US dollars.

The total is more than a hundred billion dollars!

It can be seen that a drug that can sit on the throne of medicine king can bring much benefits to a company.

Jiebowei also relies on this drug, all the way from the global ranking of the 11th and [-]th to the fifth in the world now!

Ranked second is Pfizer's Aguaxaban.

A special drug for the treatment of thrombosis, developed in cooperation with the world's top ten BMS pharmaceutical companies

-The annual sales also reached [-] billion US dollars

After that, there will be no tens of billions of dollars in drugs, but there are many more than [-] billion dollars, of which Pfizer occupies four, accounting for more than a quarter!

Enli, also a drug for the treatment of arthritis and spondylitis, is to compete with Humira, and it can bring Pfizer about [-] billion US dollars every year.

Sales are also developed in cooperation with others.

Pfizer's No. [-] drug is a pneumonia-prevention drug, with annual sales of $[-] billion

The fourth is Lerica, a powerful painkiller launched by Pfizer, with annual sales of about $[-] billion.

Pfizer has nearly ten drugs with annual sales of more than one billion US dollars, including tumor treatment, anti-inflammatory, antihypertensive, cholesterol-lowering, and antifungal drugs.

Medicines, Viagra, etc.

Therefore, the treatment of thrombosis and anti-inflammation are Pfizer's two drugs with the highest revenue.

Determined, to develop these two drugs.

Opening the list of some abandoned prescriptions in the laboratory, Fu Liang began to look at the materials he had sorted out.

When he is free these days, he also uses the system to test the side effects of some discarded prescriptions and then classify them.

- Some side effects have little development value, and they are put on the shelf.

Some side effects are valuable, but those with more side effects are classified into one category. When necessary, they can be taken out to develop a new drug.

Side effects affect the reputation and sales of drugs.

- Those with few side effects are classified into one category, which will be his main research and development direction in the future.

Among these drugs, Fu Liang has found some drugs that have weak side effects on blood clots.

These Fu Liang made notes on a non-networked computer of his own, and noted the side effects of the medicine.

After a simple screening, Fu Liang found a drug for the treatment of pneumonia with the side effects of preventing platelet aggregation and dissolving fibrin.

This is also an abandoned prescription developed by Johnson & Johnson. It was stopped after the second phase of the clinical trial, because the efficacy was too weak, especially with the common treatment on the market.

Compared with medicines for pneumonia, there is no advantage.

However, in the hands of Johnson & Johnson, it is defined as an abandoned prescription and has no value for continued research and development, but in the hands of Fu Liang, it can turn waste into treasure.

But these two side effects are very small, and his energy points are not enough.

But Fu Liang's energy points were only [-] points at this time, and it would take more than [-] points to upgrade.

It will take more than a month for Shengfaling's approval to come down, and Fu Liang can't wait that long.

It seems necessary to increase the number of clinicians again.

"You said that those drugs will be clinically conducted in more countries and regions? We can start clinical trials of many drugs within a week, but Mr. Xiaofu

This is totally unnecessary.

Edward looked at Fu Liang with a puzzled look. Apart from increasing the clinical cost, what else could this be useful for?

"Mr. Xiaofu, wait until the drug is launched in a certain region, especially the Phase IV clinical confirmation after the launch is no problem, and then go to other countries and regions to apply for it.

Please list will be easier.

"And this will not delay the future sales of the drug, after all, it is still under patent protection.

"Many drugs don't do particularly well in the early stages of the market, because people always have concerns about some new drugs, and Pfizer has not seized on this recently.

Are you attacking you fiercely?

"Even if you increase the number of clinicians, you cannot convince everyone that your drug is absolutely safe.

Edward thought that Fu Liang wanted to let people know the safety of Xinming Pharmaceutical's new drugs by increasing the number of clinical patients, but this was simply impossible.

, the number of clinical patients is only more than [-], an increase of hundreds or even thousands has little impact.

Even if it is clinical in many countries and regions around the world,

"Mr. Xiao Fu, I know that Pfizer is targeting you recently, because Pfizer's painkiller market is about to be completely eroded by our Supain.